Deep Vein Thrombosis in Severe Motor and Intellectual Disabilities Patients and Its Treatment by Anticoagulants of Warfarin Versus Edoxaban
| Autor: | Takeshi Miyanomae, Mashio Nakamura, Hiroshi Fujita, Hiroaki Murata, Akiko Kada, Hideo Kaneko, Hiromitsu Ohmori, Tomoki Takechi, Yukihiro Koretsune, Hidekazu Taniguchi, Ryo Sumimoto, Nozomi Sano, Masao Kumode, Tomoe Shinagawa, Naoyuki Tanuma, Yoshitami Sanayama, Akiko M. Saito, Keiko Maruhashi, Michiko Inoue, Noboru Takizawa, Akiko Mizukami, Akiko Wakisaka |
|---|---|
| Jazyk: | angličtina |
| Rok vydání: | 2019 |
| Předmět: |
Deep vein
030204 cardiovascular system & hematology Sudden death deep vein thrombosis 03 medical and health sciences chemistry.chemical_compound 0302 clinical medicine Edoxaban Medicine duplex ultrasonography cardiovascular diseases oral anticoagulants Adverse effect severe motor and intellectual disabilities business.industry Warfarin General Medicine medicine.disease Thrombosis medicine.anatomical_structure 030228 respiratory system chemistry Anesthesia Subcutaneous hemorrhage Original Article business Lower limbs venous ultrasonography medicine.drug |
| Zdroj: | Annals of Vascular Diseases |
| ISSN: | 1881-6428 1881-641X |
| Popis: | Objective: Patients with severe motor and intellectual disabilities (SMID) often develop complications, including paralysis of the extremities due to abnormal muscular tonicity. Furthermore, the incidence of sudden death, which may be caused by pulmonary thromboembolism (PTE), is approximately 4.2%. Deep vein thrombosis (DVT) is attracting attention as an embolic source. In this study, DVT was confirmed in SMID patients by lower extremity venous ultrasound. The oral anticoagulant, warfarin, and novel oral anticoagulant, edoxaban tosilate hydrate, were administered, and their efficacies and safeties were evaluated. Materials and Methods: DVT patients were randomly allocated to warfarin and edoxaban groups. The frequency of hemorrhagic events and incidence of adverse events were investigated to evaluate efficacy and safety. Results: DVT was detected in 14 (8.4%) out of 167 patients. Four (0.067/person-month) hemorrhagic events occurred in the warfarin group from subcutaneous hemorrhage due to bruises caused by postural changes. Three (0.042/person-month) events occurred in the edoxaban group due to nasal hemorrhage caused by tracheal aspiration. There was no significant difference (p=0.5383) between groups. Conclusion: No significant differences were observed in hemorrhagic events between SMID patients with DVT treated with warfarin and edoxaban. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|